avapro has been researched along with Arteriosclerosis in 15 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All participants had baseline diabetic nephropathy, overt proteinuria, and hypertension and were recruited between 1996 and 1999." | 2.71 | Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. ( Bostom, AG; Friedman, AN; Hunsicker, LG; Selhub, J, 2005) |
| " At the end of the follow-up, blood samples were taken for plasma lipid dosing and aorta samples for histology." | 1.38 | Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. ( Breisse, M; Canet-Soulas, E; Corot, C; Kaye, E; Lancelot, E; Majd, Z; Provost, N; Sigovan, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 13 (86.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sigovan, M | 1 |
| Kaye, E | 1 |
| Lancelot, E | 1 |
| Corot, C | 1 |
| Provost, N | 1 |
| Majd, Z | 1 |
| Breisse, M | 1 |
| Canet-Soulas, E | 1 |
| Pons, S | 1 |
| Hagège, A | 1 |
| Fornes, P | 1 |
| Gervais, M | 1 |
| Giudicelli, JF | 1 |
| Richer, C | 1 |
| Martin, G | 2 |
| Dol, F | 2 |
| Marés, AM | 2 |
| Berezowski, V | 1 |
| Staels, B | 2 |
| Hum, DW | 1 |
| Schaeffer, P | 2 |
| Herbert, JM | 2 |
| Candido, R | 1 |
| Allen, TJ | 1 |
| Lassila, M | 1 |
| Cao, Z | 1 |
| Thallas, V | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Golledge, J | 1 |
| McCann, M | 1 |
| Mangan, S | 1 |
| Lam, A | 1 |
| Karan, M | 1 |
| Wassmann, S | 1 |
| Czech, T | 1 |
| van Eickels, M | 1 |
| Fleming, I | 1 |
| Böhm, M | 1 |
| Nickenig, G | 1 |
| Solini, A | 1 |
| Santini, E | 1 |
| Ferrannini, E | 1 |
| Mezzetti, A | 1 |
| Fazia, M | 1 |
| Cipollone, F | 1 |
| Friedman, AN | 2 |
| Hunsicker, LG | 2 |
| Selhub, J | 2 |
| Bostom, AG | 2 |
| Ando, H | 1 |
| Fujimura, A | 1 |
| Hope, S | 1 |
| Brecher, P | 1 |
| Chobanian, AV | 1 |
| Goldsmith, DJ | 1 |
| Reidy, J | 1 |
| Scoble, J | 1 |
| Cazaubon, C | 1 |
| Nisato, D | 1 |
| Bidouard, JP | 1 |
| Janiak, P | 1 |
| Ortlepp, JR | 1 |
| Breuer, J | 1 |
| Eitner, F | 1 |
| Kluge, K | 1 |
| Kluge, R | 1 |
| Floege, J | 1 |
| Hollweg, G | 1 |
| Hanrath, P | 1 |
| Joost, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00021918] | 0 participants | Observational | 2001-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for avapro and Arteriosclerosis
| Article | Year |
|---|---|
[New insights on the molecular mechanisms of type-1 angiotensin II receptor blockers and their contribution to atherosclerotic plaque stabilization].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compoun | 2004 |
C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; Biphenyl Compounds; C-R | 2005 |
Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteriosclerosis; Biphenyl Compounds; Cardiovascular Syst | 2005 |
12 other studies available for avapro and Arteriosclerosis
| Article | Year |
|---|---|
Anti-inflammatory drug evaluation in ApoE-/- mice by ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Biphenyl Comp | 2012 |
Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Biphenyl Comp | 2003 |
Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Apolipoproteins E; Arteri | 2004 |
Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aortic Diseas | 2004 |
Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis.
Topics: Aged; Angiotensin II; Arteriosclerosis; Biphenyl Compounds; Blotting, Western; Carotid Stenosis; Car | 2004 |
Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arterioscleros | 2004 |
Enhanced angiotensin II-mediated effects in fibroblasts of patients with familial hypercholesterolemia.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biphenyl Compounds | 2005 |
[PPARgamma-activating properties of angiotensin receptor blockers].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimi | 2006 |
Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1999 |
Renal arterial intervention and angiotensin blockade in atherosclerotic nephropathy.
Topics: Aged; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arterioscleros | 2000 |
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Apolipoproteins E; Arteri | 2001 |
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |